How Much Does Saxenda Cost in Mississippi in 2026?

Saxenda Retail Pricing in Mississippi

The Novo Nordisk list price for Saxenda is $1,349 per month across all U.S. markets, and Mississippi retail pharmacies reflect that number almost exactly. This buys a five-pen carton supplying 30 days at the full maintenance dose of 3 mg daily.

Mississippi ranks among the states with the highest adult obesity prevalence. The CDC's 2023 Behavioral Risk Factor Surveillance System data placed the state's adult obesity rate at 40.1%, one of only a handful of states exceeding 40% 1. That epidemiologic burden means demand for GLP-1 receptor agonist therapy is high, yet access remains constrained by cost. Unlike semaglutide 2.4 mg (Wegovy), which commands a list price above $1,300, Saxenda occupies a similar price tier without the once-weekly dosing convenience. Patients filling at retail without insurance coverage can expect to pay the full $1,349 at chain pharmacies including CVS, Walgreens, and Walmart locations throughout Jackson, Gulfport, Hattiesburg, and Tupelo.

Pharmacy benefit managers sometimes negotiate net prices below list, but those discounts flow to the insurer, not the cash-pay patient. A patient walking into a Mississippi pharmacy without coverage will see a price within $20 of the list price in most cases.

What the SCALE Trial Data Tell Us About Value

Before committing $1,349 per month, Mississippi patients should understand the clinical evidence supporting that spend. The SCALE Obesity and Prediabetes trial (N=3,731) randomized adults with BMI ≥30 (or ≥27 with comorbidity) to liraglutide 3 mg or placebo, both alongside lifestyle intervention 2.

At 56 weeks, the liraglutide group lost a mean of 8.0% of body weight versus 2.6% with placebo. Over 63% of liraglutide-treated patients achieved ≥5% weight loss, compared with 27% on placebo. The trial also demonstrated a 66% reduction in progression from prediabetes to type 2 diabetes over three years of treatment, a finding with particular relevance for Mississippi, where the CDC estimates 13.6% of adults carry a diabetes diagnosis 3.

The FDA approved Saxenda in December 2014 based on these data 4. The approved dosing protocol requires a five-week titration: 0.6 mg daily for one week, increasing by 0.6 mg each subsequent week until reaching 3 mg. Patients who do not lose at least 4% of baseline weight by 16 weeks should discontinue the drug per the label.

That 16-week rule matters financially. Four months of Saxenda at list price totals approximately $5,396. If a patient has not responded by that point, continuing therapy wastes both money and time.

Mississippi Medicaid: No Coverage for Saxenda

Mississippi Medicaid does not cover Saxenda for chronic weight management. This exclusion is not unique to Mississippi. The majority of state Medicaid programs either exclude anti-obesity medications outright or impose prior authorization criteria so restrictive that approval is rare.

The Mississippi Division of Medicaid's preferred drug list categorizes anti-obesity agents as a non-covered therapeutic class. No prior authorization pathway exists to override this exclusion for Saxenda specifically. Patients enrolled in Mississippi Medicaid who need pharmacotherapy for obesity face a coverage gap that forces them toward either full cash-pay pricing or alternative treatment approaches.

Dr. Caroline Apovian, then co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, stated in an Endocrine Society clinical practice guideline: "The exclusion of anti-obesity medications from insurance formularies represents a significant barrier to evidence-based obesity treatment and perpetuates the treatment gap" 5. Mississippi's coverage posture fits that pattern precisely.

For Medicaid enrollees, the Novo Nordisk savings card is not an option. Manufacturer copay assistance programs universally exclude government-insured patients, including those on Medicaid, Medicare, and Tricare. That restriction leaves Mississippi Medicaid beneficiaries without a viable path to branded Saxenda at reduced cost.

Commercial Insurance Coverage in Mississippi

Coverage varies widely among private plans operating in Mississippi. Blue Cross Blue Shield of Mississippi, the state's dominant commercial carrier, has included GLP-1 receptor agonists on some formulary tiers, but Saxenda coverage typically requires prior authorization and documented failure of lifestyle intervention.

Standard prior authorization criteria across most Mississippi commercial plans require:

• A documented BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)
• Documentation of at least six months of structured diet and exercise without adequate weight loss
• Prescriber attestation that the medication will be used alongside continued lifestyle modification

Even with approval, formulary placement matters. Plans that place Saxenda on a specialty tier may assign copays of $150 to $300 per month. Plans with percentage-based coinsurance on specialty drugs could leave patients responsible for 25% to 40% of the list price, translating to $337 to $540 monthly.

Patients should call the number on the back of their insurance card and ask specifically: "Is liraglutide 3 mg (Saxenda) covered under my pharmacy benefit, and what is my estimated copay at a preferred pharmacy?" That single call can prevent a surprise at the pharmacy counter.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card that can reduce out-of-pocket costs for commercially insured patients. The program has shifted terms multiple times since its launch, and 2026 terms should be verified directly at the Novo Nordisk patient assistance portal.

Historically, the savings card has covered copays up to a set monthly maximum, with annual caps ranging from $200 to $500 per fill depending on the program year. Patients with no insurance are sometimes eligible for a separate cash-pay discount, though reductions from the $1,349 list price through this route have been modest.

Eligibility requirements are straightforward but exclude several groups:

• Government-insured patients (Medicaid, Medicare Part D, Tricare, VA)
• Patients whose plans do not cover Saxenda at all (the card typically requires an adjudicated pharmacy claim)
• Residents of Massachusetts, due to state-specific marketing regulations

Mississippi patients with commercial coverage and a formulary that includes Saxenda should activate the card before their first fill. The card stacks on top of insurance, reducing whatever copay or coinsurance remains after the plan pays its share.

Compounded Liraglutide 3 mg in Mississippi

Compounded liraglutide 3 mg is available through licensed 503A compounding pharmacies serving Mississippi patients. A 503A pharmacy operates under a patient-specific prescription from a licensed prescriber. This is legal in Mississippi, and multiple compounding pharmacies both within the state and in neighboring states ship to Mississippi addresses.

Compounded versions of GLP-1 receptor agonists became a major market force during the 2023-2025 shortage period. The FDA's drug shortage list included semaglutide, and 503A and 503B compounders responded by producing both semaglutide and liraglutide formulations. Liraglutide compounding predates the semaglutide shortage, as liraglutide itself is not patented in a way that prevents compounding under standard 503A rules when prescribed on a patient-specific basis 6.

Pricing for compounded liraglutide 3 mg varies by pharmacy, but patients have reported costs ranging from $150 to $450 per month, a significant discount from the $1,349 branded price. The American Association of Clinical Endocrinology has noted that compounded peptides may differ in purity, sterility testing frequency, and excipient profiles from FDA-approved products 7. Patients considering this route should confirm that the compounding pharmacy holds current state board licensure and follows USP 797 sterile compounding standards.

A prescription is required. Mississippi-licensed physicians, nurse practitioners, and physician assistants can write prescriptions for compounded liraglutide 3 mg. Telehealth prescribers licensed in Mississippi can also issue these prescriptions, which are then filled by a compounding pharmacy that ships directly to the patient.

Telehealth Access in Mississippi

Mississippi permits telehealth prescribing of Saxenda and compounded liraglutide 3 mg. The state expanded telehealth regulations during the COVID-19 pandemic, and those expansions have largely been codified into permanent law.

For weight management specifically, telehealth offers a practical advantage in Mississippi, where rural counties may lack endocrinologists or obesity medicine specialists. Sixty of Mississippi's 82 counties are classified as medically underserved by the Health Resources and Services Administration 8. Telehealth removes the geographic barrier, connecting patients in the Delta region or southern Mississippi pine belt with prescribers who specialize in obesity pharmacotherapy.

The typical telehealth weight management visit includes a medical history review, BMI calculation, discussion of comorbidities, and a treatment plan. Most telehealth platforms operating in Mississippi charge $99 to $199 for an initial consultation, with follow-up visits at $49 to $99. These visits are separate from medication cost.

Patients should verify that the telehealth provider is licensed specifically in Mississippi. The Mississippi State Board of Medical Licensure requires an active Mississippi license for any provider prescribing to a patient physically located in the state, regardless of where the provider sits.

Cost Reduction Strategies for Mississippi Patients

Paying $1,349 per month is not the only option. Mississippi patients can reduce their Saxenda costs through several approaches, listed from most to least impactful.

Switch to a covered GLP-1 if available. If a patient's insurance covers semaglutide (Wegovy) or tirzepatide (Zepbound) but not Saxenda, switching to a covered agent saves more than any discount card. Liraglutide, semaglutide, and tirzepatide all target GLP-1 receptors. The STEP 1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo, a larger effect size than Saxenda's 8.0% in SCALE 9.

Use the Novo Nordisk savings card. For commercially insured patients, this is the simplest immediate savings step. Activation takes five minutes online.

Consider compounded liraglutide 3 mg. At $150 to $450 per month through a licensed 503A pharmacy, this route offers the same active molecule at a fraction of branded cost.

Explore patient assistance programs. Novo Nordisk's Patient Assistance Program (PAP) provides free Saxenda to uninsured patients meeting income criteria, generally at or below 400% of the federal poverty level. A Mississippi household of one at 400% FPL in 2026 earns approximately $62,400 annually. Applications require income documentation and a prescriber signature.

Fill during the titration period strategically. Because the first four weeks of Saxenda require sub-therapeutic doses (0.6 mg to 2.4 mg daily), a single five-pen carton can last longer than 30 days if the titration schedule is followed precisely. Some patients stretch their first carton to six or seven weeks, reducing the per-month cost during the initiation phase.

How Saxenda Compares to Other GLP-1 Options on Cost

Mississippi patients choosing among GLP-1 receptor agonists should compare not just efficacy but monthly outlay. Wegovy (semaglutide 2.4 mg) carries a list price of approximately $1,349 per month. Zepbound (tirzepatide) lists at approximately $1,059 per month. Saxenda sits at $1,349 per month. All three require prior authorization from most insurers 10.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends semaglutide 2.4 mg or tirzepatide as first-line pharmacotherapy when available, based on superior weight loss efficacy compared with liraglutide 3 mg 11. Liraglutide 3 mg remains a reasonable option for patients who cannot tolerate or access semaglutide or tirzepatide, or whose insurance formulary favors Saxenda.

Dr. W. Timothy Garvey, chair of the Endocrine Society's obesity guideline panel, noted: "Treatment selection should be individualized based on efficacy, tolerability, patient preference, and cost. Access barriers, not clinical evidence, often drive treatment decisions in obesity care" 11.

For a Mississippi patient with no insurance coverage for any GLP-1 agent, compounded liraglutide at $150 to $450 per month represents the lowest-cost entry point into GLP-1 therapy. That price difference, potentially saving $900 or more monthly, is the single largest variable in the cost equation.